Welcome to the all-new Vetlearn

  • Vetlearn is becoming part of NAVC VetFolio.
    Starting in January 2015, Compendium and
    Veterinary Technician articles will be available on
    NAVC VetFolio. VetFolio subscribers will have
    access to not only the journals, but also:
  • Over 500 hours of CE
  • Community forums to discuss tough cases
    and networking with your peers
  • Three years of select NAVC Conference
  • Free webinars for the entire healthcare team

To access Vetlearn, you must first sign in or register.


  Sign up now for:
Become a Member

Veterinary Forum August 2009 (Vol 26, No 8)

Early Denamarin study results suggest hepatoprotection during chemotherapy

    EDGEWOOD, Md. — Preliminary data from a clinical trial suggest that Denamarin (Nutramax Laboratories, Inc.) can be used to protect against lomustine (CCNU)-induced hepatotoxicity in dogs. The study is being performed at the University of California, Davis, Veterinary Medical Teaching Hospital, and the initial results were recently presented at the American College of Veterinary Internal Medicine (ACVIM) Annual Forum in Montreal, Quebec, Canada. Denamarin is the combination of S-adenosylmethionine (SAMe) and silybin.

    Most dogs treated with the chemotherapeutic agent CCNU experience liver enzyme elevation, according to the company. Elevation of certain liver enzymes, such as alanine transferase (ALT), is a key indicator of liver trauma. Significant enzyme elevation may lead to a discontinuation, delay or reduction in chemotherapy. The ongoing clinical trial was designed to evaluate Denamarin as a hepatoprotectant in dogs diagnosed with neoplasia that are undergoing CCNU therapy.

    The trial consists of two groups of randomly assigned dogs. Dogs in Group 1 receive Denamarin beginning at the start of CCNU therapy. Group 2 dogs do not receive Denamarin unless they develop a Grade IV hepatotoxicity.

    Results of a planned interim analysis completed on the first 30 dogs enrolled revealed that starting Denamarin when CCNU therapy was instituted (Group 1 dogs) appeared to provide hepatoprotection. While the mean post-therapy ALT elevation for Group 1 was 119 IU/L (p=0.1), for Group 2 dogs the post-therapy ALT level was 815 IU/L (p=0.046). Chemotherapy was altered due to elevated liver enzymes in three Group 2 dogs but only one dog in Group 1.

    "We are extremely pleased by the initial findings of this research," said Robert Devlin, DVM, director of the veterinary science division of Nutramax. "The use of Denamarin with chemotherapy looks to help protect liver function and allow for successful completion of therapy and hopefully a longer, happier life for the pet. We look forward to the results of the full study."

    The SAMe and silybin in Denamarin support and maintain hepatic function by such mechanisms as increasing levels of glutathione, the liver's main detoxifying agent; promoting protein synthesis; and stimulating bile flow. Denamarin is useful as part of a polymodal approach to the management of liver health.

    Denamarin is available for both dogs and cats in an enteric-coated tablet. Denamarin for Dogs is also now offered in a chewable tablet formulation. For more information, visit www.nutramaxlabs.com.

    NEXT: FDA takes action against Teva Animal Health


    Did you know... In dogs, up to 40% of enrofloxacin is converted to ciprofloxacin.

    These Care Guides are written to help your clients understand common conditions. They are formatted to print and give to your clients for their information.

    Stay on top of all our latest content — sign up for the Vetlearn newsletters.
    • More